Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Drug

Transcenta Holding Ltd Secures Global Clinical Trial Approvals for Osemitamab in Gastric Cancer

Fineline Cube Jul 11, 2023

China-based Transcenta Holding Ltd has reported receiving clinical trial approvals from China’s Center for Drug...

Company

Pentax Medical to Establish Endoscope Manufacturing and R&D Site in Shanghai

Fineline Cube Jul 11, 2023

Japan-based Pentax Medical, a division of the Hoya Group specializing in endoscopic products, has announced...

Company Deals

Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”

Fineline Cube Jul 10, 2023

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal...

Company Drug

Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy

Fineline Cube Jul 10, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Accepted for US FDA Review in IDE Process

Fineline Cube Jul 10, 2023

Ningbo-based structural heart disease intervention device manufacturer, Jenscare Scientific Co., Ltd (HKG: 9877), has announced...

Company Medical Device

Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System

Fineline Cube Jul 10, 2023

China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung...

Company Deals Digital

Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education

Fineline Cube Jul 10, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership...

Company Drug

HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors

Fineline Cube Jul 10, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I...

Company

GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility

Fineline Cube Jul 10, 2023

China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing...

Policy / Regulatory

China’s NAFR Enhances Tax Benefits for Private Health Insurance Purchases

Fineline Cube Jul 7, 2023

The National Administration of Financial Regulation (NAFR) in China has issued a Notification indicating that...

Company Deals

Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs

Fineline Cube Jul 7, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in...

Company Medical Device

Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device

Fineline Cube Jul 7, 2023

Singapore-based Genesis MedTech has announced that it has received market approval in China for its...

Company Drug

Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval

Fineline Cube Jul 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study

Fineline Cube Jul 7, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development

Fineline Cube Jul 7, 2023

China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...

Company Deals

ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion

Fineline Cube Jul 7, 2023

China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to...

Company Medical Device

Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China

Fineline Cube Jul 7, 2023

Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced...

Company Deals

Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007

Fineline Cube Jul 7, 2023

Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...

Company Deals

Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy

Fineline Cube Jul 6, 2023

Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced...

Policy / Regulatory

CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts

Fineline Cube Jul 6, 2023

The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...

Posts pagination

1 … 499 500 501 … 660

Recent updates

  • GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership
  • AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.